CSIMarket



Eli Lilly And Company  (LLY)
Other Ticker:  
 

Cumulative Eli Lilly And's Total Debt to Equity for Trailing Twelve Months Period

LLY's Total Debt to Equity for Trailing Twelve Months Period and Total Debt, Equity growth


Select the Comparisons : Select the Ratio:

LLY Total Debt to Equity for Trailing Twelve Months Period

(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
Y / Y Equity Growth 29.95 % 33.28 % 57.16 % 59.21 % 55.98 %
Y / Y Total Debt Growth 1.81 % 1.88 % 1.74 % 0.97 % 1.14 %
Total Debt to Equity for Trailing Twelve Months Period 1.91 2.02 2.16 2.41 2.69
Total Ranking # 1831 # 1910 # 2012 # 1688 # 1678
Seq. Equity Growth -8.48 % 3.36 % 15.1 % 19.37 % -6.14 %
Seq. Total Debt Growth 1.85 % -2.23 % -1.17 % 3.45 % 1.92 %


Total Debt to Equity for Trailing Twelve Months Period Comment
On the trailing twelve months basis Despite net new borrowings of 1.85% Eli Lilly And managed to decrease Total Debt to Equity for Trailing Twelve Months Period in II. Quarter to 1.91, above Eli Lilly And's average Total Debt to Equity for Trailing Twelve Months Period.
Total Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 102 other companies have achieved lower Total Debt to Equity for Trailing Twelve Months Period than Eli Lilly And. While Total Debt to Equity for Trailing Twelve Months Period total ranking has improved so far to 1831, from total ranking in previous quarter at 1910.

What is Debt to Equity Ratio?
LLY Charts and Quotes
Total Debt to Equity LLY in the most recent quarter
Total Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 103
Sector # 320
S&P 500 # 1826


Total Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
1.03 0.37 0
(Sep. 30. 2009)   (Sep. 30, 2015)




Companies with similar average Total Debt to Equity for Trailing Twelve Months Period for 12 months ending Jun 30 2022, within Major Pharmaceutical Preparations Industry Total Debt to Equity for Trailing Twelve Months Period
Revance Therapeutics Inc.  4.00 
Ensysce Biosciences Inc.  3.51 
Mallinckrodt Plc  3.02 
Kala Pharmaceuticals inc.  2.90 
Societal Cdmo Inc.  2.50 
Xeris Biopharma Holdings Inc.  2.40 
Collegium Pharmaceutical inc.  2.28 
Insmed Inc  2.23 
Teva Pharmaceutical Industries Limited  2.19 
Cti Biopharma Corp.  2.14 
Heron Therapeutics Inc.  2.12 
Avadel Pharmaceuticals Plc  2.08 
Eli Lilly And Company  2.04 
Jazz Pharmaceuticals Plc  1.88 
Cure Pharmaceutical Holding Corp.  1.84 
Jaguar Health inc.  1.79 
Sarepta Therapeutics Inc.  1.73 
Axsome Therapeutics Inc.  1.67 
Global Blood Therapeutics Inc.  1.67 
Phibro Animal Health Corporation  1.64 
Avalo Therapeutics Inc.  1.63 
Apellis Pharmaceuticals Inc.  1.60 
Amicus Therapeutics inc.  1.56 
Athenex Inc.  1.47 
Zoetis Inc.  1.47 
Agile Therapeutics Inc  1.38 
Bristol myers Squibb Company  1.28 
Avid Bioservices Inc.  1.24 
Verrica Pharmaceuticals Inc.  1.24 
Travere Therapeutics Inc.  1.19 


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AFAI's Profile

Stock Price

AFAI's Financials

Business Description

Fundamentals

Charts & Quotes

AFAI's News

Suppliers

AFAI's Competitors

Customers & Markets

Economic Indicators

AFAI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071